Tumour Ablation (Cryo / RFA / Microwave)

Introduction

Tumour ablation is a way of destroying a tumour without cutting it out. Instead of an open operation, a doctor called an interventional radiologist uses imaging — ultrasound, CT, or MRI — to guide a thin needle or probe through the skin and directly into the tumour. The probe then delivers extreme cold or heat to kill the abnormal cells in place.

This guide is written for patients (and families) who already have a diagnosis and are now weighing ablation as part of their treatment plan. You may have been told that ablation is an option instead of surgery, or in addition to other treatments such as chemotherapy, radiotherapy, or immunotherapy. You may also be considering ablation because surgery is not safe or possible in your situation.

The three main forms of ablation covered here are cryoablation (freezing), radiofrequency ablation (RFA, using heat from radio waves), and microwave ablation (heat from microwave energy). They share a common principle — destroy the tumour locally while sparing as much healthy tissue as possible — but they differ in how the energy is delivered, what kinds of tumours they suit best, and what recovery looks like. The right choice depends on the type of tumour, where it sits, its size, your overall health, and a careful discussion with your treating team.

What Is Tumour Ablation?

Tumour ablation is a minimally invasive procedure that destroys tumour tissue using thermal (heat or cold) or, less commonly, chemical or electrical energy. The word “ablation” simply means removal or destruction. In this context, the tumour is not physically removed from the body; it is killed in place, and the body gradually absorbs or scars over the dead tissue over weeks to months.

The procedure is usually performed by an interventional radiologist, a doctor trained in using imaging to guide needle-based treatments. In some centres, surgical oncologists, hepatobiliary surgeons, urologists, or thoracic surgeons also perform ablation, sometimes during a laparoscopic or open operation.

Most ablations are percutaneous, meaning the probe enters through a small puncture in the skin — no surgical incision. Imaging keeps the probe on target throughout. Once positioned, the probe creates a zone of cell death (called the “ablation zone”) that is planned to cover the tumour plus a small margin of normal tissue around it, similar in concept to a surgical margin.

Ablation is generally used for relatively small tumours, often up to about 3 to 5 centimetres depending on the organ and modality, and in places where the probe can be safely guided in and out. It is part of a broader cancer care plan rather than a stand-alone solution for most patients.

Why Is Tumour Ablation Performed?

Ablation has become a recognised treatment option across several cancers and benign tumours. Major oncology and interventional radiology societies, including the Society of Interventional Radiology (SIR), the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), and the National Comprehensive Cancer Network (NCCN), describe ablation as an accepted treatment for selected patients in the following situations.

Liver tumours

Ablation is widely used for primary liver cancer (hepatocellular carcinoma, or HCC) when the tumour is small and surgery or liver transplant is not the immediate plan. The European Association for the Study of the Liver (EASL) and NCCN guidelines describe ablation as a curative-intent option for very early and early-stage HCC, particularly when tumours are 3 cm or smaller. Ablation is also used for selected liver metastases — especially from colorectal cancer — when only a small number of lesions are present and surgical removal is not preferred.

Kidney tumours

For small kidney tumours (typically up to about 4 cm), ablation is described in urology and interventional radiology guidelines as an alternative to partial nephrectomy (surgical removal of part of the kidney), particularly in older patients, in patients with only one functioning kidney, or in those with medical conditions that make surgery higher risk.

Lung tumours

Ablation is used for selected early-stage lung cancers in patients who cannot tolerate surgery, and for a limited number of lung metastases from other cancers. Stereotactic body radiotherapy (SBRT) is often the more commonly used non-surgical option in lung cancer, but ablation has a role in specific situations.

Bone tumours

For painful bone metastases that have not responded well to radiotherapy or medication, ablation — usually combined with cement injection (cementoplasty) when needed for structural support — can reduce pain significantly. Ablation is also a recognised treatment for osteoid osteoma, a benign but painful bone tumour, particularly in adolescents and young adults.

Other uses

Ablation is also performed for selected adrenal tumours, soft tissue tumours, certain thyroid nodules, breast fibroadenomas in some settings, and benign tumours such as desmoid tumours. The evidence base varies across these uses, and decisions are made case by case.

Two broad goals: cure or control

Ablation can be performed with two different intentions:

• Curative intent — the goal is to destroy the entire tumour, similar to surgical removal. This is most realistic for small, well-defined tumours.
• Palliative or local control intent — the goal is to relieve symptoms (such as pain from bone metastases) or to slow disease in a specific spot, without aiming to cure the cancer overall.

Knowing which goal your team has in mind helps you understand what the procedure is meant to achieve and how success will be measured afterwards.

Who Is a Candidate?

Whether ablation is suitable in any individual case is a clinical decision that depends on a number of factors. Teams usually consider:

• Tumour size. Smaller tumours are generally better suited to ablation because the heating or freezing zone can reliably cover the whole tumour with a safety margin. Most curative-intent ablations are reserved for tumours under about 3 to 5 cm, depending on the organ and modality.
• Number of tumours. A small number of lesions (often up to three to five) is more likely to be treated with ablation than widespread disease.
• Tumour location. Tumours near major blood vessels, the bowel, the gallbladder, the diaphragm, the ureter, or important nerves require careful planning, and sometimes additional techniques to protect nearby structures.
• Underlying organ function. Liver function in HCC, kidney function in renal tumours, and lung function in lung tumours all influence what is safe.
• General fitness. Ablation is often suitable for patients who are not fit for surgery because of age, heart disease, lung disease, or other conditions, since it avoids general anaesthesia in many cases and is much less invasive.
• Bleeding risk. Blood-thinning medications usually need to be paused before the procedure, and severe clotting disorders may need to be corrected first.

The decision is usually made in a multidisciplinary tumour board, where surgeons, medical oncologists, radiation oncologists, interventional radiologists, radiologists, and pathologists review the case together. The treatment plan that comes out of this discussion is shaped by current guidelines and the specifics of the individual.

Alternatives to Tumour Ablation

Ablation is one option in a wider menu of treatments. Depending on your diagnosis, alternatives that doctors may consider include the following.

Surgical removal

Surgery to remove the tumour (resection) or part of the organ is the long-standing standard of care for many solid tumours when it is technically possible and the patient is fit enough. For liver and kidney cancers in particular, surgery remains a primary option for patients who can tolerate it.

Stereotactic body radiotherapy (SBRT)

SBRT delivers very precise, high-dose radiation in a small number of sessions. It is used for selected lung, liver, kidney, spine, and other tumours. SBRT and ablation are sometimes interchangeable in early-stage disease, and sometimes one is clearly preferred — for example, SBRT is often favoured for early-stage lung cancer in non-surgical candidates.

Transarterial therapies

For liver tumours, doctors may also use transarterial chemoembolisation (TACE) or transarterial radioembolisation (TARE / Y-90). These deliver chemotherapy or radioactive beads through the artery that feeds the tumour. They are often used for larger or more numerous liver tumours where ablation alone is not enough.

Systemic therapy

Chemotherapy, targeted therapy, immunotherapy, and hormone therapy work on the whole body. They are often the main treatment for cancers that have spread widely. Ablation may be added as a local treatment alongside systemic therapy in some cases.

Active surveillance

For small, slow-growing tumours — particularly some small kidney tumours and certain thyroid nodules — close monitoring with regular imaging is sometimes the chosen approach, with treatment only if the tumour grows or changes.

The right choice is rarely between ablation and just one alternative. It is usually a comparison across several options, weighing the chance of controlling the disease against the side effects, recovery time, and impact on organ function.

Types of Tumour Ablation

Radiofrequency Ablation (RFA)

Radiofrequency ablation uses high-frequency electrical current to heat tumour tissue. An electrode is placed into the tumour, and current flows from the electrode through the tissue and back to grounding pads on the skin. The friction of electrons moving through tissue produces heat — typically 60–100°C — which causes cell death.

RFA was the first widely adopted thermal ablation method and has the longest track record. It is most established in:

• Liver tumours (HCC and some metastases), particularly tumours up to about 3 cm
• Small kidney tumours
• Osteoid osteoma, where it is a well-established treatment
• Some thyroid nodules and lung tumours

RFA tends to produce a smaller ablation zone than microwave ablation and can be affected by the “heat sink” effect, in which blood flowing through a nearby vessel carries heat away and can leave a sliver of tumour incompletely treated. For this reason, RFA can be less reliable for tumours sitting directly against larger vessels.

Microwave Ablation (MWA)

Microwave ablation uses electromagnetic waves in the microwave frequency range to vibrate water molecules in the tissue, producing heat. The antenna is placed inside the tumour, and heating begins quickly — temperatures inside the ablation zone can exceed 100°C.

Compared with RFA, microwave ablation generally:

• Heats tissue faster and to higher temperatures
• Produces a larger ablation zone in a similar treatment time
• Is less affected by the heat sink effect, so it can be more reliable near blood vessels
• Does not require grounding pads

Microwave ablation is increasingly used in the liver and lung, and for selected kidney, bone, and adrenal tumours. In many centres, microwave ablation has become the preferred thermal option for liver tumours, particularly those slightly larger or near vessels, although RFA remains widely used and effective for many cases.

Cryoablation

Cryoablation works by freezing rather than heating. Probes are placed into the tumour, and pressurised argon gas is circulated through them to drop the tip temperature to roughly −40°C or lower. Ice forms inside and around the tumour cells, damaging them directly and disrupting the small blood vessels that feed them. A controlled thaw, often using helium, follows, and the freeze–thaw cycle is usually repeated.

Cryoablation has some distinctive properties:

• The “ice ball” that forms can be seen clearly on CT and MRI, so the treated zone is visible in real time
• It tends to be less painful during and after the procedure than heat-based methods in some settings
• It is well suited to bone, kidney, soft tissue, and chest wall locations
• It can shape ablation zones using multiple probes, which is useful for irregularly shaped tumours

Cryoablation is particularly common for small kidney tumours and painful bone metastases, and is also used in lung, breast, prostate, and soft tissue tumours in selected cases. Because freezing can trigger a small amount of bleeding within the ablation zone, cryoablation may not be preferred when bleeding risk is high.

How is the modality chosen?

There is no universal “best” modality. The choice is shaped by:

• Organ and tumour type: for example, microwave is increasingly favoured in liver, cryoablation in kidney and bone, and RFA remains a strong choice for osteoid osteoma and small liver lesions
• Tumour location: closeness to vessels, bowel, nerves, or the surface of an organ
• Tumour size and shape
• Operator experience and the equipment available at the centre
• Patient factors: bleeding risk, prior treatments, anaesthesia tolerance

Your interventional radiologist will explain which modality they are recommending in your case and why.

Preparing for Tumour Ablation

Preparation typically begins one to two weeks before the procedure and includes the following.

Imaging review and planning

Your team will study recent CT, MRI, ultrasound, or PET scans to confirm the tumour’s position, size, and relationship to nearby structures. In some cases, additional imaging is ordered to plan the safest needle path.

Pre-procedure tests

Common tests include:

• Blood tests, including a full blood count, clotting profile, and kidney and liver function tests
• An ECG and sometimes a chest X-ray
• Anaesthetic review if general anaesthesia or deep sedation is planned

Medication adjustments

Blood thinners (such as warfarin, clopidogrel, apixaban, rivaroxaban, or even aspirin in some situations) are usually paused before the procedure to reduce bleeding risk. The exact timing depends on the medication and your medical history; your team will give specific instructions. Some patients on warfarin may need short-term injectable anticoagulants as a bridge. Diabetes medications, particularly insulin, may need to be adjusted for the fasting period.

Fasting

You are usually asked not to eat for six to eight hours before the procedure, and not to drink clear fluids in the final two hours.

Consent

The interventional radiologist will explain the procedure, the goals, the risks, and the alternatives. This is a good time to ask:

• What is the goal of my ablation — cure or control?
• Which modality will be used, and why?
• What kind of anaesthesia will I have?
• How long will I stay in hospital?
• What follow-up will I need?

What Happens During Tumour Ablation

Anaesthesia

Ablation can be performed under:

• Local anaesthesia with sedation — you are awake but drowsy; the skin is numbed; pain medication is given through a drip
• General anaesthesia — you are fully asleep; often preferred for lung ablation, larger liver ablations, and cases where breath-holding is needed
• Spinal or regional blocks — occasionally used, especially for bone ablations

Positioning and imaging

You are positioned on the table to give the best access to the tumour. Imaging — typically CT, ultrasound, or a combination — is used to identify the target. The skin is cleaned with antiseptic, and a sterile drape is placed.

Probe placement

The skin and deeper tissues are numbed with local anaesthetic. A small skin nick is made, and the probe is advanced into the tumour under image guidance. The position is checked and rechecked. For larger tumours, more than one probe may be placed so that the ablation zones overlap.

Delivering the energy

Once the probe is in place:

• In RFA, current is switched on and the temperature in the tissue rises over several minutes. Treatment cycles typically last 10 to 20 minutes per site.
• In microwave ablation, the antenna heats the tissue rapidly — treatment cycles are often shorter, sometimes only a few minutes per site.
• In cryoablation, freezing usually proceeds in two or three cycles of about 10 minutes each, alternating freeze and thaw. The ice ball is monitored on imaging to confirm it covers the tumour and a margin.

Protective techniques

When the tumour sits close to vulnerable structures, the team may use techniques such as:

• Hydrodissection — injecting sterile water or dextrose to push nearby bowel or other organs away
• Pneumodissection — using gas to create a similar protective gap
• Nerve and ureter monitoring or cooling
• Track ablation at the end, in which the probe is heated as it is withdrawn to reduce bleeding and the risk of tumour cells being dragged along the needle path

Finishing up

Once the team is satisfied that the ablation zone covers the tumour with an adequate margin, the probes are removed. A small dressing is placed over the skin entry point. A post-procedure scan may be done in the same session to confirm the result and check for early complications.

Most ablations take between one and three hours in total, including setup, anaesthesia, the ablation itself, and final imaging.

Recovery and Healing

The first hours

You will be observed in a recovery area for several hours. Vital signs, pain, and the skin entry site are checked. If you had general anaesthesia, you may feel groggy as the medication wears off. Common sensations include:

• A dull ache, throbbing, or burning at the treatment site
• Shoulder or back discomfort after liver or kidney procedures, sometimes from irritation of the diaphragm
• Mild nausea
• A low-grade fever in the first day or two (called the post-ablation syndrome — see below)

Hospital stay

Many ablations are done as day-care or overnight stays. Liver, kidney, and bone ablations often involve one night in hospital. Lung ablations may need longer if a small lung collapse (pneumothorax) develops and needs a drain. Your team will tell you what to expect for your specific procedure.

Post-ablation syndrome

A flu-like reaction is common for a few days after ablation — low-grade fever, fatigue, muscle aches, mild nausea, and reduced appetite. This happens because the body is breaking down the destroyed tumour tissue. It usually settles within a week and is managed with rest, fluids, and simple pain relief such as paracetamol if recommended by your team.

Going home

By the time you are discharged, most patients can walk, eat, and manage basic self-care. You will be given instructions on:

• Caring for the skin entry site (usually a small dressing for a day or two)
• When to restart your usual medications, especially blood thinners
• Pain relief at home
• Activity restrictions — typically avoiding heavy lifting and strenuous exercise for one to two weeks, with longer restrictions for some bone and lung procedures
• Signs that need urgent review (see Risks and Complications)

Return to normal activity

Risks and Complications

Ablation is generally a low-risk procedure compared with open surgery, but it is not risk-free. Risks fall into several categories.

Common, usually mild

• Pain or aching at the treatment site for several days
• Bruising at the skin entry point
• Post-ablation syndrome (low-grade fever, fatigue) for up to a week
• Small amount of bleeding at the puncture site

Less common but important

• Bleeding inside the organ or around it, occasionally requiring transfusion or, rarely, embolisation to stop
• Infection or abscess at the ablation site — uncommon but can require antibiotics or drainage
• Pneumothorax (collapsed lung) — the most common complication of lung ablation; many cases are small and resolve on their own, but some need a chest drain
• Injury to nearby structures such as the bowel, bile ducts, gallbladder, ureter, nerves, or skin — protective techniques during the procedure reduce this risk
• Bile leak after liver ablation, particularly with central tumours
• Cryoshock — a rare reaction after large-volume cryoablation, with low blood pressure, clotting changes, and kidney effects
• Tumour seeding along the needle track — rare, and made less likely by track ablation

Procedure-specific notes

• Lung ablation: pneumothorax is common; cough and bloody sputum can occur
• Kidney ablation: blood in the urine for a few days is common; injury to the collecting system or ureter is uncommon but recognised
• Liver ablation: temporary changes in liver function tests are common; in patients with cirrhosis, liver decompensation is possible
• Bone ablation: nerve injury near the spine; rarely, fracture of weakened bone, sometimes prevented by cementing the area afterwards

Incomplete ablation

Sometimes the entire tumour is not destroyed, especially when the tumour is larger, irregularly shaped, or near a vessel. Follow-up imaging looks specifically for this. If residual or recurrent tumour is found, repeat ablation is often possible — one of the practical advantages of ablation is that it can usually be repeated.

When to seek urgent review

Contact your team or go to an emergency department if, after going home, you develop:

• Severe or worsening pain that is not controlled by your usual pain relief
• A high fever (above 38.5°C) or fever that persists beyond a week
• Heavy bleeding from the skin entry site, or bright red blood in your urine or stool
• Breathlessness, chest pain, or coughing up blood
• Yellowing of the skin or eyes after liver ablation
• Confusion, dizziness, or fainting

Life After Tumour Ablation

Follow-up imaging

Imaging is the main way to check the result. A scan is usually done within the first one to three months and then at regular intervals — often every three months for the first year, and less frequently after that, depending on the cancer type and your overall plan.

On these scans, the team looks for:

• Complete coverage of the original tumour by the ablation zone
• Absence of contrast uptake within the treated area (which would suggest residual tumour)
• New lesions elsewhere in the same organ
• Signs of disease elsewhere in the body

Tumour markers and blood tests

For some cancers — for example, alpha-fetoprotein in HCC or CEA in colorectal metastases — blood tests track tumour activity alongside imaging. Liver function, kidney function, and other blood tests are checked depending on the organ treated.

Combining with other treatments

Ablation is often part of a wider plan. It may be combined with:

• Surgery, before or after, for different lesions
• TACE or TARE for liver tumours
• Systemic therapy for metastatic disease
• Radiotherapy for bone or other sites
• Immunotherapy, where there is emerging interest in whether local ablation may help the immune system recognise the cancer

What success looks like

Doctors often use the term local control — meaning the treated tumour does not regrow in the same spot. For small, well-positioned tumours, local control with ablation is good and is comparable to surgery in several studies, particularly for small HCC and small kidney cancers. For larger tumours or those near vessels, the chance of incomplete treatment or local recurrence is higher.

Ablation does not prevent new tumours from forming elsewhere in the same organ or the body. Continued surveillance is important, especially in conditions like cirrhosis where the underlying organ remains at risk of new tumours.

Emotional aspects

Even when a procedure goes smoothly, living with a cancer diagnosis is demanding. Scans every few months can be stressful. Many patients find it useful to:

• Plan something neutral or pleasant after scan days
• Bring a family member or friend to results appointments
• Speak openly with their team about anxiety or low mood; psychological support is part of comprehensive cancer care
• Connect with patient organisations relevant to their cancer type

Frequently Asked Questions

Is tumour ablation a cure?

It can be, for small, well-defined tumours treated with curative intent. Doctors consider it a curative-intent option in early-stage HCC, small kidney cancers, osteoid osteoma, and selected other settings. Whether it works as a cure in any individual case depends on tumour size, position, and biology, and on whether the underlying condition (such as cirrhosis) continues to produce new tumours.

How is ablation different from surgery?

Surgery removes the tumour and surrounding tissue from the body. Ablation destroys the tumour in place using cold or heat through a needle. Surgery generally involves a larger incision, longer recovery, and more impact on organ function, but it allows the tumour to be examined in detail afterwards. Ablation is less invasive, has a shorter recovery, and can often be repeated, but does not provide a removed specimen for full pathology.

Which is better — cryoablation, RFA, or microwave?

There is no single answer. Each has strengths. Microwave generally heats faster and is less affected by nearby blood vessels. RFA has the longest track record and works well for small tumours and osteoid osteoma. Cryoablation is well suited to kidney and bone, and the ice ball can be seen clearly on imaging. The choice is matched to the organ, the tumour, and the operator’s experience.

Will I be awake during the procedure?

It depends. Some ablations are done under local anaesthesia with sedation, in which case you are drowsy but may be partly aware. Others, particularly lung ablations or longer liver ablations, are done under general anaesthesia. Your anaesthetist will discuss the plan with you in advance.

How long does it take to recover?

Most people are home within one day and back to light activity within a few days. Return to full normal activity usually takes one to two weeks. The post-ablation syndrome — fatigue, low fever, mild aches — can last about a week.

Can ablation be repeated if the tumour comes back?

Yes, in many cases. One of the practical advantages of ablation is repeatability. If follow-up imaging shows a new or residual tumour and ablation remains technically possible, the procedure can usually be performed again. The decision depends on overall disease status and organ function.

Will I lose part of my organ?

Ablation destroys the tumour plus a small margin of surrounding tissue. The treated area scars but the rest of the organ is preserved. This is one reason ablation is attractive in the kidney and liver, where preserving function matters.

Will I need other cancer treatments as well?

Often, yes. Ablation is usually part of a wider plan that may include surveillance, systemic therapy, surgery, or radiotherapy. Your tumour board will outline what the full plan looks like in your case.

Is ablation safe if I have other medical conditions?

Ablation is often chosen specifically because it is gentler than surgery and can be offered to patients who are older or who have heart, lung, or kidney conditions. Even so, the team will assess your fitness for sedation or anaesthesia, your bleeding risk, and your organ function before recommending it.

How soon will I know if the ablation worked?

An immediate post-procedure scan can show the size and shape of the ablation zone, but the most useful information comes from a follow-up scan one to three months later, when the team looks for any sign of residual or recurrent tumour. Tumour markers in the blood may add information for some cancers.

Conclusion

Tumour ablation has become an established part of cancer care for selected patients. By delivering extreme cold or heat directly into a tumour through a needle, it offers a way to treat certain cancers without the larger incisions, longer recovery, and greater impact on organ function that surgery can bring. Cryoablation, radiofrequency ablation, and microwave ablation each have their place, and the right choice depends on the kind of tumour, where it sits, your overall health, and the experience of the team.

The most useful conversations with your team will focus on the goal of the procedure (cure or control), why a particular modality has been suggested, what success will look like on follow-up scans, and how ablation fits into the wider plan for your cancer. Ablation rarely stands alone — surveillance, systemic treatment, and sometimes additional local treatments work alongside it. With careful selection, careful technique, and careful follow-up, it is one of the meaningful tools available in modern cancer care.